Molecular pathology of melanocytic skin cancer

Skin Cancer: A Practical Approach

Volumn , Issue , 2014, Pages 59-74

  Palmieri, Giuseppe ^a   Sarantopoulos, Peter ^b   Barnhill, Raymond ^b   Cochran, Alistair ^b  

^a CNR   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927632124     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7357-2_4     Document Type: Chapter

References (73)

1. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene. 2003;22:3099-112.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687-701.
3. Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol. 2005;23:2669-75.
4. Curado MP, Edwards B, Shin HR, et al., editors. Cancer incidence in five continents, vol. IX, International Agency for Research on Cancer (lARC) Scientific Publications, No. 160. Lyon: lARC; 2007.
5. Rigel DS. Epidemiology of melanoma. Semin Cutan Med Surg. 2010;29:204-9.
6. Linos E, Swetter S, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666-74.
7. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331:481.
8. de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. BMJ. 2005;331:698.
9. Palmieri G, Casula M, Sini MC, et al. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med. 2007;11:1052-68.
10. Giehl K. Oncogenic Ras in tumor progression and metastasis. Biol Chem. 2005;386:193-205.
11. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase- dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140: 209-21.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417: 949-54.
13. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1): 19-20.
14. E600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720-4.
15. Patton EE, Widlund HR, Kutok JL, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol. 2005;15:249-54.
16. Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132:363-74.
17. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009; 15: 294-303.
18. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-47.
19. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7:2876-83.
20. Ascierto PA, De Maio E, Bertuzzi S, et al. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011;9:32.
21. Pomerantz J, Schreiber-Agus N, Lie'geois NJ. The Ink4a tumor suppressor gene product, 19Arf, interacts with MDM2 and neutralizes DM2's inhibition of p53. Cell. 1998;92:713-23.
22. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 1998;92:725-34.
23. Palmieri G, Capone ME, Ascierto ML, et al. Main roads to melanoma. J Transl Med. 2009;7:86.
24. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-31.
25. Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res. 2008;21:525-33.
26. Meyle KD, Guldberg P. Genetic risk factors for melanoma. Hum Genet. 2009;126:499-510.
27. Fargnoli MC, Gandini S, Peris K, et al. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer. 2010;46: 1413-20.
28. Scott MC, Wakamatsu K, Ito S, et al. Human melano- cortin 1 receptor variants, receptor function and melanocyte response to UV radiation. J Cell Sci. 2002;n5:2349-55.
29. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12:406-14.
30. Hauser JE, Kadekaro AL, Kavanagh RJ, et al. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment CeU Res. 2006;19:303-14.
31. Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science. 2006;313:521-2.
32. Fargnoli MC, Pike K, Pfeiffer RM, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol. 2008;128:2485-90.
33. Thomas NE, Kanetsky PA, Edmiston SN, et al. Relationship between germline MC1R variants and BRAF-mutant melanoma in a North Carolina population-based study. J Invest Dermatol. 2010; 130: 1463-5.
34. Scherer D, Rachakonda PS, Angelini S, et al. Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. J Invest Dermatol. 2010;130:2844-8.
35. Hacker E, Hayward NK, Dumenil T, et al. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol. 2010;130: 241-8.
36. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113-22.
37. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
38. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005;24:7435-42.
39. Mirmohammadsadegh A, Marini A, Nambiar S, et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res. 2006;66:6546-52.
40. Tsao H, Goel V, Wu H, et al. Genetic interaction between NRAS and BRAF mutations and PTEN/ MMAC1 inactivation in melanoma. J Invest Dermatol. 2004;122:337-41.
41. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117-22.
42. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005;433:764-9.
43. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol. 2005;168:35-40.
44. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF stimulated melanocyte and melanoma cell proliferation. J Cell Biol. 2005;170:703-8.
45. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell. 2002;109:707-18.
46. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 2004;6:565-76.
47. Wellbrock C, Rana S, Paterson H, et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One. 2008;3: 2734.
48. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-10.
49. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25: 6817-30.
50. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13:738-47.
51. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109:2700-7.
52. Cilloni D, Martinelli G, Messa F, et al. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica. 2007;92:1224-9.
53. McNulty SE, del Rosario R, Cen D, et al. Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 2004;17(2):173-80.
54. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor- kappaB and tumor progression. Cancer Res. 2002;62:7335-42.
55. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopon- tin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix met alloproteinase-9 activation. J Biol Chem. 2004;279:38921-35.
56. Uffort DG, Grimm EA, EUerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway- dependent iNOS expression in human melanoma. J Invest Dermatol. 2009;129:148-54.
57. Chami L, Lassau N, Chebil M, Robert C. Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment. Clin Cosmet Investig Dermatol. 2011;4:1-6.
58. Cochran AJ, Starz H, Ohsie SJ, et al. Pathologic reporting and special diagnostic techniques for melanoma. Surg Oncol Clin N Am. 2006;15:231-51.
59. Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology. 2004;36:485-90.
60. Balch CM, Gershenwald JE, Atkins MB, et al., editors. AJCC cancer staging manual. 7th ed. American Joint Committee on Cancer. Springer: New York; 2010. p. 325-44.
61. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-44.
62. Elder DE, Xiaowei X. The approach to the patient with a difficult melanocytic lesion. Pathology. 2004;36:428.
63. Pinkel D, Albertson D. Array comparative genomic hybridization and its applications in cancer. Nat Genet Suppl. 2005;37:S11-7.
64. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163:1765-70.
65. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization in melanoma. Arch Pathol Lab Med. 2011;135:830-7.
66. Gaiser T, Kutzner H, Palmedo G, et al. Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod Pathol. 2010;23:413-9.
67. North JP, Vetto JT, Murali R, et al. Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma. Am J Surg Pathol. 2011;35:1146-50.
68. Koh SS, Opel ML, Wei J-P, et al. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin- embedded tissue. Mod Pathol. 2009;22:538-46.
69. Koh SS, Wei J-P, Li X, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol. 2012;25:828-37.
70. Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463: 191-6.
71. Wei X, Walia V, Lin JC, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011;43:442-6.
72. Miller AJ, Mihm MC. Melanoma. N Engl J Med. 2006;355:51-65.
73. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol. 2008;26:2890-4.